Pyrimidine-Purine Composite Nucleoside for Aptamer Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing nucleoside derivatives and methods, such as SELEX, often fail to produce binding nucleic acid molecules with sufficient binding ability for certain targets, limiting their application in aptamer production.
Innovation Solution
A novel nucleoside derivative with a purine ring structure and specific hydrocarbon and functional group linkages is introduced, enhancing the binding ability of polynucleotides to targets, which are synthesized using this derivative and selected through a modified SELEX method.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If natural nucleosides and known derivatives are used in SELEX method, then the process is simple and familiar, but binding ability to certain targets is insufficient
Solution Approach 1:
The patent applies composite materials by combining a pyrimidine ring (thymine) with a purine ring (guanine) through a linker to create a composite nucleoside structure. This composite structure integrates functional elements from both pyrimidine and purine nucleosides, enabling enhanced binding ability to targets that neither natural nucleoside type could achieve alone, while maintaining compatibility with existing SELEX methodology
Solution Approach 2:
The patent applies parameter changes by modifying the chemical structure parameters of nucleosides - specifically changing the ring system from single pyrimidine or purine to a combined pyrimidine-purine system with variable linkers. This structural parameter change fundamentally alters the binding properties, enabling the nucleoside to achieve sufficient binding ability for targets where conventional nucleosides fail
2Reliability
If modified nucleoside derivatives are introduced to improve binding ability, then binding performance increases, but synthesis complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the complex nucleoside structure into separable components: a pyrimidine ring portion, a purine ring portion, and a linker connecting them. This segmentation allows each component to be synthesized and characterized independently, then assembled into the final compound, significantly simplifying the manufacturing process compared to attempting to synthesize the entire complex structure in one step
Solution Approach 2:
The patent applies the intermediary principle by using a linker as a mediator between the pyrimidine and purine rings. This linker serves as a flexible bridge that can be independently synthesized and then used to connect the two ring systems, simplifying the overall synthesis by breaking down the complex molecule into manageable fragments that can be assembled through standardized coupling reactions
Data Source
Figure 1~2
Figure 3
Figure 4A~4B
AI summary
The present invention provides a novel nucleoside derivative or a salt thereof, a polynucleotide synthesis reagent, a method for producing a polynucleotide, a polynucleotide, and a method for producing a binding nucleic acid molecule. The nucleoside derivative or a salt thereof of the present invention is represented by the following chemical formula (1): where in the chemical formula (1), Su is an atomic group having a sugar skeleton at a nucleoside residue or an atomic group having a sugar phosphate skeleton at a nucleotide residue, and may or may not have a protecting group, L1 and L2 are each independently a straight-chain or branched, saturated or unsaturated hydrocarbon group having 2 to 10 carbon atoms, X1 and X2 are each independently an imino group (-NR1-), an ether group (-O-), or a thioether group (-S-), and the R1 is a hydrogen atom or a straight-chain or branched, saturated or unsaturated hydrocarbon group having 2 to 10 carbon atoms.